Cadexomer iodine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
(what is this?) (verify) |
WikiDoc Resources for Cadexomer iodine |
Articles |
---|
Most recent articles on Cadexomer iodine Most cited articles on Cadexomer iodine |
Media |
Powerpoint slides on Cadexomer iodine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cadexomer iodine at Clinical Trials.gov Trial results on Cadexomer iodine Clinical Trials on Cadexomer iodine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cadexomer iodine NICE Guidance on Cadexomer iodine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cadexomer iodine Discussion groups on Cadexomer iodine Patient Handouts on Cadexomer iodine Directions to Hospitals Treating Cadexomer iodine Risk calculators and risk factors for Cadexomer iodine
|
Healthcare Provider Resources |
Causes & Risk Factors for Cadexomer iodine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cadexomer iodine is an iodophor that is produced by the reaction of dextrin with epichlorhydrin coupled with ion-exchange groups and iodine. It is a water-soluble modified starch polymer containing 0.9% iodine, calculated on a weight-weight basis, within a helical matrix.[1]
History
Cadexomer iodine was developed in the early 1980s in Sweden by Perstorp AB, and given the name Iodosorb. The product was shown to be effective in the treatment of venous ulcers,.[2][3] More recently, it has been shown in studies in animals and humans that, unlike the iodophor povidone-iodine, Iodosorb causes an acceleration of the healing process in chronic human wounds. This is due to an increase in epidermal regeneration and epithelialization in both partial-thickness and full-thickness wounds.[4] In this way cadexomer iodine acts as a cicatrizant.
Properties
When formulated as a topical wound dressing Iodosorb adsorbs exudate and particulate matter from the surface of granulating wounds and, as the dressing becomes moist, iodine is released. The product thus has the dual effect of cleansing the wound and exerting a bactericidal action.
Uses
In addition to other manufacturers, Smith & Nephew distributes cadexomer iodine as Iodosorb and Iodoflex in many countries of the world for the treatment and healing of various types of wounds. The dosage forms are a paste dressing, an ointment and a gel, all of which contain 0.9% iodine.
See also
References
- ↑ Merck Index, 14th Edition, p262 Merck & Co. Inc.
- ↑ Skog, E. et al. (1983). A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. British Journal of Dermatology 109, 77. PMID 6344906
- ↑ Ormiston, M.C., Seymour, M.T., Venn, G.E., Cohen, R.I. and Fox, J.A. (1985). Controlled trial of Iodosorb in chronic venous ulcers. British Medical Journal (Clinical Research Edition) 291, 308-310. PMID 3962169
- ↑ Drosou Anna, Falabella Anna, and Kirsner Robert S. (2003) Antiseptics on Wounds: An area of controversy. Wounds 159(5) 149-166. http://cme.medscape.com/viewarticle/456300_2 Retrieved 02/03/2009
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Infobox drug tracked parameters
- Iodine compounds
- Drug